VANCOUVER, Feb. 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. today announced that it has filed notification with the U.S. Department of Justice and the Federal Trade Commission of its intention to acquire privately held American Medical Instruments Holdings, Inc. (AMI), in compliance with the pre-merger notification requirements of the Hart-Scott- Rodino Antitrust Improvements Act of 1976. AMI also filed its notification today.
On February 1, 2006, Angiotech announced that it had entered into a definitive agreement to acquire AMI for $785 million in cash.
The acquisition of AMI significantly enhances and diversifies Angiotech’s revenue base and gives the company global manufacturing, marketing and sales capabilities. A strongly managed company, AMI has global operations in 12 locations and four countries, including over 550,000 square feet of modern manufacturing operations.
About Angiotech Pharmaceuticals
Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical company pioneering the combination of pharmaceutical compounds with medical devices and biomaterials to both create novel solutions for poorly addressed disease states and improve surgical outcomes. To find out more about Angiotech Pharmaceuticals, Inc. , please visit our website at www.angiotech.com.
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continue,” “estimate,” “expects,” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.
FOR ADDITIONAL INFORMATION: --------------------------- Analysts and Investors: Todd Young, Vice President Investor Relations and Communications Angiotech Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Media: Colleen Beauregard Waggener Edstrom Bioscience (503) 443-7863, Email: colleenb@wagged.com
Angiotech Pharmaceuticals, Inc.
CONTACT: Analysts and Investors: Todd Young, Vice President InvestorRelations and Communications, Angiotech Pharmaceuticals, Inc., (604)221-7676 ext 6933; Media: Colleen Beauregard, Waggener Edstrom Bioscience,(503) 443-7863, Email: colleenb@wagged.com
